Literature DB >> 34519031

Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin.

I Pospischil1, E Guenova2,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34519031      PMCID: PMC9292945          DOI: 10.1111/bjd.20695

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   11.113


× No keyword cloud information.
Exosomes are small extracellular vesicles containing proteins, lipids and nucleic acids that facilitate cell–cell communication, influence local and distant microenvironments, and have implications in cancer pathogenesis. MicroRNAs (miRNAs), which act as key post‐transcriptional regulators of gene expression, are an important part of the exosome content. , In recent years, evidence has accumulated that dysregulated miRNA expression interferes with tumour immunity and plays a crucial role in the pathogenesis of diverse malignancies including cutaneous T‐cell lymphoma (CTCL). , While data addressing the role of exosomes in the most common CTCL, mycosis fungoides (MF), are only just increasing, some miRNAs have already caught attention as promising candidates for much needed diagnostic and prognostic biomarkers and novel therapeutic targets. , , In this issue of the BJD, Moyal and colleagues elegantly implement transmission electron microscopy and nanoparticle tracking analysis to track the presence of tumour‐derived exosomes in MF and to gain insights into their miRNA profile in vitro and ex vivo. Besides demonstrating for the first time the existence of MF‐derived exosomes, the study identifies miR‐1246 as a major miRNA in the MF cell line exosomal content and confirms the importance of miR‐155 in the pathogenesis of MF (Figure 1).
Figure 1

Route of mycosis fungoides (MF)‐derived microRNA (miRNA). Formation of exosomes is one way for MF tumour cells to discharge their cell‐free miRNA to the extracellular space. Besides proteins, lipids and nucleic acids, miR‐155 and especially miR‐1246 were identified as major cargo of MF‐derived exosomes. After their release from MF cells, exosomes are incorporated by benign and malignant recipient cells of the immune system, which markedly increases the migratory capabilities of these cells. Exosomal miR‐155 significantly contributes to this migratory effect.

Route of mycosis fungoides (MF)‐derived microRNA (miRNA). Formation of exosomes is one way for MF tumour cells to discharge their cell‐free miRNA to the extracellular space. Besides proteins, lipids and nucleic acids, miR‐155 and especially miR‐1246 were identified as major cargo of MF‐derived exosomes. After their release from MF cells, exosomes are incorporated by benign and malignant recipient cells of the immune system, which markedly increases the migratory capabilities of these cells. Exosomal miR‐155 significantly contributes to this migratory effect. In general, miR‐155 overexpression is one of the best characterized features of MF disease progression and is associated with increased cancer proliferation and tumour cell survival. , , Based on this knowledge, a prospective phase II clinical trial already explores the efficacy of the anti‐miR‐155 compound Cobomarsen (MRG‐106) in MF (https://clinicaltrials.gov/ct2/show/NCT03713320). Thus, the study of Moyal and colleagues provides further evidence for the general role of miR‐155 in MF and especially its capacity to enhance cell migration of malignant MF cells. Interestingly, both miR‐155 and miR‐1246 are present in MF cell line exosomes. However, in elucidating specifically the role of tumour‐derived exosomal miRNAs (exomiRNAs), Moyal and colleagues expand their research beyond in vitro cell‐line data to ex vivo disease‐stage dependent analysis of MF exosomes and their exomiRNA content in MF patient plasma. Of interest, in the plasma of 18 patients with advanced MF, manifesting clinically with plaque and tumour skin lesions, expression of exomiR‐1246 but not exomiR‐155 was significantly higher than in plasma of healthy individuals. Regarding total circulating cell‐free miRNA (cfmiRNA), plasma levels of both cfmiR‐155 and cfmiR‐1246 were higher in patients with advanced MF than in healthy individuals, notably independent of the patient’s blood tumour burden. Collectively, while this novel study performed by Moyal and colleagues does not yet fully explain the relevance of the MF‐derived exomiRNA, the observations especially on cfmiRNAs do suggest a direct translational application in clinics. Both cfmiR‐155 and cfmiR‐1246, together with exomiR‐1246, should be considered as MF‐associated molecular biomarkers for advanced skin disease. They may play a role as novel therapeutic targets and open a perspective towards the development of diagnostic approaches such as liquid biopsy for CTCL.

Author Contribution

Isabella Maria Pospischil: Conceptualization (equal); Project administration (equal); Visualization (equal); Writing‐original draft (equal); Writing‐review & editing (equal). Emmanuella Guenova: Conceptualization (equal); Methodology (equal); Project administration (equal); Resources (equal); Supervision (equal); Validation (equal); Visualization (equal); Writing‐original draft (equal); Writing‐review & editing (equal).
  9 in total

Review 1.  Tumor-Derived Exosomes and Their Role in Cancer Progression.

Authors:  Theresa L Whiteside
Journal:  Adv Clin Chem       Date:  2016-04-07       Impact factor: 5.394

2.  Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.

Authors:  L Moyal; S Yehezkel; B Gorovitz; A Keren; A Gilhar; I Lubin; S Sherman; E Hodak
Journal:  Br J Dermatol       Date:  2017-05-07       Impact factor: 9.302

3.  miRNA expression profiling of mycosis fungoides.

Authors:  Marloes S van Kester; Erica Ballabio; Marchina F Benner; Xiao H Chen; Nigel J Saunders; Leslie van der Fits; Remco van Doorn; Maarten H Vermeer; Rein Willemze; Cornelis P Tensen; Charles H Lawrie
Journal:  Mol Oncol       Date:  2011-02-24       Impact factor: 6.603

4.  MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.

Authors:  Ulrik Ralfkiaer; Lise M Lindahl; Lise Lindal; Thomas Litman; Lise-Mette Gjerdrum; Charlotte Busch Ahler; Robert Gniadecki; Troels Marstrand; Simon Fredholm; Lars Iversen; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Thorbjørn Krejsgaard; Christian Glue; Mads Almose Røpke; Anders Woetmann; Lone Skov; Kirsten Grønbæk; Niels Odum
Journal:  Anticancer Res       Date:  2014-12       Impact factor: 2.480

5.  miR-155 is involved in tumor progression of mycosis fungoides.

Authors:  Lilach Moyal; Aviv Barzilai; Batia Gorovitz; Avi Hirshberg; Ninette Amariglio; Jasmine Jacob-Hirsch; Leah Maron; Meora Feinmesser; Emmilia Hodak
Journal:  Exp Dermatol       Date:  2013-06       Impact factor: 3.960

Review 6.  Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Malgorzata Bobrowicz; Christina Fassnacht; Desislava Ignatova; Yun-Tsan Chang; Florentia Dimitriou; Emmanuella Guenova
Journal:  Int Arch Allergy Immunol       Date:  2020-07-20       Impact factor: 2.749

7.  Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.

Authors:  L Moyal; C Arkin; B Gorovitz-Haris; C Querfeld; S Rosen; J Knaneh; I Amitay-Laish; H Prag-Naveh; J Jacob-Hirsch; E Hodak
Journal:  Br J Dermatol       Date:  2021-08-13       Impact factor: 11.113

8.  Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.

Authors:  Nina Dusílková; Petra Bašová; Jindřich Polívka; Ondřej Kodet; Vojtěch Kulvait; Michal Pešta; Marek Trněný; Tomáš Stopka
Journal:  Int J Mol Sci       Date:  2017-10-15       Impact factor: 5.923

Review 9.  MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Authors:  Maria Gluud; Andreas Willerslev-Olsen; Lise Mette Rahbek Gjerdrum; Lise M Lindahl; Terkild B Buus; Mads Hald Andersen; Charlotte Menne Bonefeld; Thorbjorn Krejsgaard; Ivan V Litvinov; Lars Iversen; Jürgen C Becker; Jenny L Persson; Sergei B Koralov; Thomas Litman; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.